Nipro Competitors and Similar CompaniesClear all
Nipro's competitors and similar companies include West Pharmaceutical Services, Eisai, Kuraray, Takeda, Astellas Pharma and Nikkiso.
 Nipro Nipro Corporation (ニプロ株式会社) is a company that has expertise in medical devices, pharmaceuticals, pharma packaging, and regenerative medicine business. |  West Pharmaceutical Services West Pharmaceutical Services is a company that designs and manufactures drug packaging and delivery systems. |  Eisai Eisai (エーザイ株式会社) is a research-based human healthcare company that discovers, develops, packages, and markets pharmaceutical products. |  Kuraray Kuraray (株式会社クラレ) is a company that specializes in the production and sale of chemicals and polyvinyl alcohol (PVA) fiber. |  Takeda Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. |  Astellas Pharma Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions. | ||
Founding Date | Founding Date 1954 | Founding Date 1923 | Founding Date 1941 | Founding Date 1926 | Founding Date 1781 | Founding Date 1923 | Founding Date 1953 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||||
Locations | Locations Tokyo, JP HQ Victoria, AU Beveren, BE Seneffe, BE Zwijndrecht, BE São Paulo, BR Shanghai, CN see more | Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Vilvoorde, BE São Paulo, BR Markham, CA Beijing, CN see more | |||||
Employees | Employees 38,117 | Employees 10,6001% decrease | Employees 11,067 | Employees 11,941 | Employees 47,4554% decrease | Employees 14,754 | Employees 8,1203% decrease |
Valuation ($) | Valuation ($) 1.5 b | Valuation ($) 23.1 b | Valuation ($) 9.6 b | Valuation ($) 4.4 b | Valuation ($) 43.7 b | Valuation ($) 20.8 b | Valuation ($) 440.7 m |
Financial | |||||||
Revenue (est.) | Revenue (est.) ¥660.5b (FY, 2026) | Revenue (est.) $3.1b (FY, 2025) | Revenue (est.) ¥825.4b (FY, 2026) | Revenue (est.) ¥808.4b (FY, 2025) | Revenue (est.) ¥4.5t (FY, 2026) | Revenue (est.) ¥2.1t (FY, 2026) | Revenue (est.) ¥215.6b (FY, 2025) |
Cost of goods | Cost of goods ¥388.5b (FY, 2026) | Cost of goods $2b (FY, 2025) | Cost of goods ¥151.7b (FY, 2026) | Cost of goods ¥477b (FY, 2025) | Cost of goods ¥850.5b (FY, 2026) | Cost of goods ¥213.8b (FY, 2026) | Cost of goods ¥144.3b (FY, 2025) |
Gross profit | Gross profit ¥272b (FY, 2026) | Gross profit $1.1b (FY, 2025) | Gross profit ¥679b (FY, 2026) | Gross profit ¥331.4b (FY, 2025) | Gross profit ¥3.7t (FY, 2026) | Gross profit ¥2t (FY, 2026) | Gross profit ¥72.2b (FY, 2025) |
Net income | Net income ¥15.7b (FY, 2026) | Net income $493.7m (FY, 2025) | Net income ¥40.5b (FY, 2026) | Net income ¥5.1b (FY, 2025) | Net income ¥192b (FY, 2026) | Net income ¥291.6b (FY, 2026) | Net income ¥13.8b (FY, 2025) |
Operating ⚠ | |||||||
Filed Trials Products | Filed Trials Products N/A | Filed Trials Products N/A | Filed Trials Products 9 (Jul, 2019) | Filed Trials Products N/A | Filed Trials Products 16 (May, 2025) | Filed Trials Products N/A | Filed Trials Products N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 14 (Jul, 2019) | Phase I Trials Products N/A | Phase I Trials Products 2 (May, 2025) | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase I Trials Products (Oncology) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 11 (Jul, 2019) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 1 (FY, 2020) | Phase I Trials Products (Oncology) N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 15 (Jul, 2019) | Phase II Trials Products N/A | Phase II Trials Products 10 (May, 2025) | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase II Trials Products (Oncology) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 9 (Jul, 2019) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 1 (FY, 2020) | Phase II Trials Products (Oncology) N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 14 (Jul, 2019) | Phase III Trials Products N/A | Phase III Trials Products 17 (May, 2025) | Phase III Trials Products N/A | Phase III Trials Products N/A |
Phase III Trials Products (Oncology) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 10 (Jul, 2019) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 4 (Oct, 2020) | Phase III Trials Products (Oncology) N/A |
For sources of this data, please see the company profile
View Company Profiles
West Pharmaceutical Services
HQ
Exton, US
Employees
10,600↓ 1% decrease
West Pharmaceutical Services is a company that designs and manufactures drug packaging and delivery systems.
View companyEisai
HQ
Tokyo, JP
Employees
11,067
Eisai (エーザイ株式会社) is a research-based human healthcare company that discovers, develops, packages, and markets pharmaceutical products.
View companyKuraray
HQ
Tokyo, JP
Employees
11,941
Kuraray (株式会社クラレ) is a company that specializes in the production and sale of chemicals and polyvinyl alcohol (PVA) fiber.
View companyTakeda
HQ
Tokyo, JP
Employees
47,455↓ 4% decrease
Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products.
View company